News coverage about Second Sight Medical Products (NASDAQ:EYES) has trended somewhat positive on Friday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Second Sight Medical Products earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 44.3226524625518 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Second Sight Medical Products (NASDAQ EYES) traded down $0.03 during trading hours on Friday, hitting $1.88. The stock had a trading volume of 211,400 shares, compared to its average volume of 511,150. The company has a market capitalization of $108.50, a PE ratio of -2.94 and a beta of 3.71. Second Sight Medical Products has a 52 week low of $0.90 and a 52 week high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The company had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $1.54 million. Second Sight Medical Products had a negative return on equity of 184.87% and a negative net margin of 565.12%. sell-side analysts forecast that Second Sight Medical Products will post -0.55 earnings per share for the current year.

Several research firms have recently weighed in on EYES. Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Monday, January 8th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Second Sight Medical Products in a report on Monday, November 6th.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.